# Allena Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/allena-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Newton, US
- Website: www.allenapharma.com
- Total disclosed funding: $93M
- Latest round: Series C (Dec 5, 2015)
- Investors on record: 8

## About

Allena Pharmaceuticals is a biopharmaceutical company focused on developing innovative oral enzyme therapies to treat metabolic diseases, particularly those involving high oxalate and urate levels.Founded in 2011 and headquartered in Newton, US, Allena Pharmaceuticals specializes in oral enzyme therapies for metabolic conditions. The company has undergone significant funding rounds, including a notable IPO in November 2017 that raised USD 74.67 mn. The latest funding round was a Private Placement in December 2021, raising USD 2.87 mn, which brought the total amount raised to USD 2.87 mn. Allena has been involved in 15 deals up to December 2021, aiming to enhance its therapeutic offerings.Allena Pharmaceuticals specializes in the development of novel oral enzyme therapies aimed at addressing difficult-to-treat metabolic diseases, particularly enteric hyperoxaluria, hyperuricemia, and gout. The company's core offering includes a first-in-class oral biologic platform designed to reduce oxalate levels in patients suffering from enteric hyperoxaluria. Additionally, Allena is developing a non-absorbed urate-degrading enzyme aimed at breaking down urate in the gastrointestinal tract, providing a potential solution for hyperuricemia and gout patients, particularly those with reduced kidney function. The primary users of these therapies are patients diagnosed with metabolic disorders, and the company is focused on expanding its market presence within North America and Europe.Allena Pharmaceuticals operates a business model centered around partnerships and collaborations with healthcare providers and organizations focusing on metabolic diseases. The revenue structure is primarily driven by the commercialization of its enzyme therapies, including direct sales to healthcare facilities and prescriptions through pharmacies. The company actively engages healthcare providers to prescribe its proprietary oral biologic therapies, enhancing market access through collaborations and partnerships.Allena Pharmaceuticals plans to utilize the funding from its most recent Private Placement in December 2021 to advance its lead product candidate, ALLN-177, targeting secondary hyperoxaluria in patients with a history of calcium oxalate kidney stones, currently in Phase 3 clinical trials. The company also aims to explore additional indications for ALLN-177, such as oxalate nephropathy and primary hyperoxaluria, while developing new product candidates leveraging its non-systemic oral protein therapeutic platform. Allena is focused on expanding its market reach in North America and Europe to enhance accessibility to its innovative therapies.

## Funding rounds

- Series C, Dec 5, 2015, $53M — Frazier Healthcare Partners, HBM Partners, Wellington Management, Fidelity Investments, Pharmstandard International S.A., Partner Fund Management
- Series B, Nov 12, 2014, $25M — Frazier Healthcare Partners, HBM Partners, Bessemer Venture Partners, Third Rock Ventures, Pharmstandard International S.A.
- Series A, Nov 16, 2011, $15M — Frazier Healthcare Partners, Bessemer Venture Partners, Third Rock Ventures

## Investors

- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A, Series B, Series C
- Bessemer Venture Partners (https://capitalatlas.ai/funds/bessemer-venture-partners) — Series A, Series B
- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A, Series B
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B, Series C
- Pharmstandard International S.A. — Series B, Series C
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series C
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series C
- Partner Fund Management — Series C